Floatz logo

Loratadine

Leukemia

Wake Forest University Health SciencesSmall moleculeDormant
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB

View all 50 →

Same molecule, other indications

Loratadine is also rated in:

Fabry diseaseDormant
BB
Indicative ·
69 / 100
View asset →
breast cancerDormant
BB
Indicative ·
69 / 100
View asset →
Moderate or Severe Submental FullnessDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →